pharmaceuticals

pharmaceuticals Articles

Pacira Pharmaceuticals announced that it achieved an amicable resolution with the FDA for a lawsuit filed earlier this year that effectively lifts the restriction on its Exparel.
Neothetics Inc. (NASDAQ: NEOT) was absolutely crashed in Tuesday’s session after announcing top-line results from a late stage trial that fell short.
Spark Therapeutics has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for a secondary offering.
AcelRx intends to pursue an ARX-04 indication for moderate-to-severe pain in a medically supervised setting. However, this might be farther out than investors anticipated.
Atara Biotherapeutics announced results from its Phase 2 proof-of-concept clinical trial for PINTA 745 for the treatment of protein energy wasting in patients with end stage renal disease.
Akebia Therapeutics led the bulls early on Monday following news of what looks like a big commercialization partnership in Asia.
Bluebird Bio, Idera Pharmaceuticals and others stood out from other biotech stock with incredible gains or losses over the course of the past week.
Cara Therapeutics saw its stock rise in Wednesday’s session on statistically significant Phase 2 results, but the delight of investors may be short lived.
The November 30 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was up.
Baxalta was rising in Wednesday’s trading session on news of a key U.S. Food and Drug Administration (FDA) approval.
Aeterna Zentaris has amended is filing with the U.S. Securities and Exchange Commission (SEC) for its secondary offering.
TherapeuticsMDwas leading the health care sector in Tuesday’s session on positive top-line results from one of its late-stage trials.
Onconova Therapeutics led the bulls early in Tuesday’s trading session on positive data from an ongoing Phase 1/2 clinical trial.
Brokerage firm Jefferies has released its top pharmaceutical picks for the coming year and what to expect.
Bluebird Bio absolutely tanked in Monday's trading session, based on preclinical and manufacturing data from the American Society of Hematology Annual Meeting.